Abstract
The tissue specificity and age-related etiology of Shiga toxin (Stx)-induced pathology strongly implicate receptor binding as a major determinant of Stxinduced hemolytic uremic syndarome (HUS) (1). In this review, Shiga toxin receptor binding is considered in relation to the following: (1) the multivalency and multiple valencies of the Shiga toxin B- subunit pentamer and the molecular basis of its specificity, including the important role played by the lipid moiety of globotriaosyl ceramide (Gb3) and its plasma membrane microenvironment; (2) the internalization of the toxin-receptor complex and subsequent intracellular trafficking; (3) the role of Gb3 in cell signaling pathways; (4) the upregulation of Gb3 synthesis and Stx sensitivity in cancers, particularly drug-resistant cancers and the involvement of the P-glycoprotein in Gb3 biosynthesis; (5) the ability of Gb3 synthesis to be upregulated by cytokines or short-chain fatty acids to increase Stx susceptibility; 6) Gb3 as a risk factor for the development of HUS, because in summa, these properties define the mechanism by which Shiga toxemia results in clinical sequellae. However, these properties also imbue Stx with characteristics that can be utilized as tools in cell biology to measure aspects of homeostasis and to provide new methods for immunization and DNA transfection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lingwood C. A. (1994) Verotoxin-binding in human renal sections. Nephron 66, 21ā28
Waddell T., Cohen A., and Lingwood C. A. (1990) Induction of Verotoxin sensitivity in receptor deficient cell lines using the receptor glycolipid globotriosyl ceramide. Proc. Natl. Acad. Sci. USA 87, 7898ā7901
Keusch G., Jacewicz M., Acheson D., Donohue-Rolfe A., Kane A., and McCluer R. (1995) Globotriasylceramide,Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect. Immun. 63, 1138ā1141
DeGrandis S., Law H., Brunton J., Gyles C., and Lingwood C. A. (1989) Globotetraosyl ceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 264, 12,520ā12,525
Lingwood C. A., Law H., Richardson S., Petric M., Brunton J. L., DeGrandis S., et al. (1987) Glycolipid binding of purified and recombinant Escherichia coli-produced Verotoxin in vitro. J. Biol. Chem. 262, 8834ā8839
Waddell T., Head S., Petric M., Cohen A., and Lingwood C. A. (1988) Globotriosyl ceramide is specifically recognized by the E. coli Verocytotoxin 2. Biochem. Biophys. Res. Commun. 152, 674ā679
Nyholm P. G., Magnusson G., Zheng Z., Norel R., Binnington-Boyd B., and Lingwood C. A. (1996) Two distinct binding sites for globotriaosyl ceramide on verotoxins: molecular modelling and confirmation by analogue studies and a new glycolipid receptor for all verotoxins. Chem. Biol. 3, 263ā275
Boyd B., Zhiuyan Z., Magnusson G., and Lingwood C. A. (1994) Lipid modulation of glycolipid receptor function: presentation of galactose Ī±1-4 galactose disaccharide for Verotoxin binding in natural and synthetic glycolipids. Eur. J. Biochem. 223, 8733ā8378
Lingwood C. A. (1996) Aglycone modulation of glycolipid receptor function. Glycoconj. J. 13, 495ā503
Armstrong G. D., Fodor E., and Vanmaele R. (1991) Investigation of Shigalike toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164, 1160ā1167
Kitov P. I., Sadowska J. M., Mulvey G., Armstrong G. D., Lingaw H., Pannu N. S., et al. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669ā672
Peter M. and Lingwood C. (2000) Apparent cooperativity in multivalent verotoxin glogotriaosyl ceramide binding: Kinetic and saturation binding experiments with radiolabelled Verotoxin [125I]-VT1. Biochim. Biophys. Acta 1501, 116ā124
Nyholm P.-G., Brunton J. L., and Lingwood C. A. (1995) Modelling of the interaction of Verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3). Int. J. Biol. Macromol. 17, 199ā205
Cummings M., Ling H., Armstrong G., Brunton J., and Read R. (1998) Modeling the carbohydrate-binding specificity of pig edema toxin. Biochemistry 37, 1789ā1799
Nyholm P.-G. and Pascher I. (1993) Steric presentation and recognition of the saccharide chains of glycolipids at the cell surface: favoured conformations of the saccharide-lipid linkage calculated using molecular mechanics (MM3). Int. J. Biol. Macromol. 5, 43ā51
Lingwood C. A., Mylvaganam M., Arab S., Khine A. A., Magnusson G., Grinstein S., et al. (1998) Shiga toxin (Verotoxin) binding to its receptor glycolipid, in Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains (Kaper J. B. and OāBrien A. D., eds.), American Society for Microbiology, Washington, DC, pp. 129ā139
Ling H., Boodhoo A., Hazes B., Cummings M., Armstronmg G., Brunton J., et al. (1998) Structure of the Shiga toxin B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37, 1777ā17788
Richardson J. M., Evans P. D., Homans S. W., and Donohue-Rolfe A. (1996) Solution structure of the carbohydrate-binding B-subunit homopentamer of Verotoxin VT-1 from E. coli. Nat. Struct. Biol. 4, 190ā193
Picking W. W., McCann J. A., Nutikka A., and Lingwood C. A. (1999) Localization of the binding site for modified Gb3 on Verotoxin 1 using fluorescence analysis. Biochemistry 38, 7177ā7184
Tyrrell G. J., Ramotar K., Toye B., Boyd B., Lingwood C. A., and Brunton J. L. (1992) Alteration of the carbohydrate binding specificity of verotoxins from Gala1-4Gal to GalNAcĪ²1-3GalĪ±1-4GĪ±1 and vice versa by site-directed mutagenesis of the binding subunit. Proc. Natl. Acad. Sci. USA 89, 524ā528
Ling H., Pannu N. S., Boodhoo A., Armstrong G. D., Clark C. G., Brunton J. L., et al. (2000) A mutant Shiga-like toxin IIe bound to its receptor Gb3: structure of a group II Shiga-like toxin with altered binding specificity. Structure 8, 253ā264
Mylvaganam M. and Lingwood C. (1999) Adamantyl globotriaosyl ceramide-a monovalent soluble glycolipid mimic which inhibits Verotoxin binding to its glycolipid receptor. Biochem. Biophys. Res. Commun. 257, 391ā394
Hansen H. C. and Magnusson G. (1999) Synthesis of some aglycon analogs of globotriosylceramide. Carbohydr. Res. 322, 181ā189
Bast D. J., Banerjee L., Clark C., Read R. J., and Brunton J. L. (1999) The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit. Mol. Microbiol. 32, 953ā960
Soltyk A., MacKenzie C. R., Wolski W., Hirama T. and Brunton J. A mutational analysis of the globotriaosyl ceramide binding sites of Verotoxin VT1. Submitted.
Sandvig K., Olnes S., Brown J., Peterson O., and van Deurs B. (1989) Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J. Cell Biol. 108, 1331ā1343
Khine A. A. and Lingwood C. A. (1994) Capping and receptor mediated endocytosis of cell bound verotoxin (Shiga-like toxin) 1; chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. J. Cell. Physiol. 161, 319ā332
Sandvig K., Garred Ć., Prydz K., Kozlov J., Hansen S., and van Deurs B. (1992) Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358, 510ā512
Arab S. and Lingwood C. (1998) Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to Verotoxin: sodium butyrate or selection of drug resistance may induce nuclear toxin targeting via globotriosyl ceramide fatty acid isoform traffic. J. Cell. Physiol. 177, 646ā660
Sandvig K., Ryd M., Garred O., Schweda E., and Holm P. K. (1994) Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J. Cell Biol. 126, 53ā64
Lingwood C. A., Khine A. A., and Arab S. (1998) Globotriaosyl ceramide (Gb3) expression in human tumor cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. Acta Biochem. Polon. 45, 351ā359
Falguieres T., Baron C., Mallard F., Lingwood C., Goud B., Salamero J., et al. (2001) Cell type differences in sensitivity to Shiga toxin-mediated inhibition of protein biosynthesis can be correlated with the existence of two distinct toxin transport pathways. Mol. Biol. Cell 12, 2453ā2468
Saxena S. K., OāBrien A. D., and Ackerman E. J. (1989) Shiga toxin, Shigalike toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264, 596ā601
Bitzan M. M., Wang Y., Lin J., and Marsden P. A. (1998) Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J. Clin. Invest. 101, 372ā382
Lingwood C. A. Glycolipids and bacterial pathogenesis, in Oligosaccharides in Chemistry and Biology/A Comprehensive Handbook (Ernst B., Sinay P. and Hart G., eds.), Wiley-VCH, Weinheim, in press.
Schapiro F., Lingwood C. A., Furuya W., and Grinstein S. (1998) pH-independent targeting of glycolipids to the Golgi complex. Am. J. Physiol. 274, 319ā332
Khine, A. A. PhD thesis, University of Toronto, Canada, 2000.
Smart E. J., Ying Y.-S., Conard P. A., and Anderson R. G. W. (1994) Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J. Cell Biol. 127, 1185ā1197
Ramegowda B. and Tesh V. L. (1996) Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64, 1173ā1180
van Setten P., Monnens L., Verstraten R., van der Heuvel L., and van Hinsberg V. (1996) Effects of Verotoxin-1 on non adherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88, 174ā183
Yamasaki C., Natori Y., Zeng X.-T., Ohmura M., Yamasaki S., Takeda S., et al. (1999) Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity. FEBS Lett. 442, 231ā234
Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569ā572
Hooper N. (1999) Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae. Mol. Membr. Biol. 16, 145ā156
Brown D. and London E. (1998) Functions of lipid rafts in biological membranes. Annu. Rev. Cell. Dev. Biol. 14, 111ā136
van Setten P., van Hinsbergh V., van den Heuvel L., Preyers F., Dijkman H., Assmann K., et al. (1998) Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr. Res. 43, 759ā767
Louise C. B. and Obrig T. G. (1991) Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1b, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59, 4173ā4179
van der Kar N. C. J., Kooistra T., Vermeer M., Lesslauer W., Monnens L. A. H., and van Hinsbergh V. W. M. (1995) Tumor necrosis factor a induces endothelial galactosyl transferase activity and verocytotoxin receptors. Role of specific tumor necrosis factor receptors and protein kinase C. Blood 85, 734ā743
Keusch G. T., Acheson D. W. K., Aaldering L., Erban J., and Jacewicz M. S. (1996) Comparison of the effects of Shiga-like toxin 1 on cytokine-and butyrate pretreated human umbilical and saphenous vein endothelial cells. J. Infect. Dis. 173, 1164ā1170
Steffensen R., Carlier K., Wiels J., Levery S. B., Stroud M., Cederen B., et al. (2000) Cloning and expression of the histo-blood group Pk UDP-galactose: Galbeta 1-4Glcbeta 1-Cer alpha 1, 4-galactosyltransferase. Molecular genetic basis of the p phenotype. J. Biol. Chem. 275, 16,723ā16,729
Kojima Y., Fukumoto S., Furukawa K. T. O., Wiels J., Yokoyama K., Suzuki Y., et al. (2000) Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransfease that initiates the synthesis of globo series glycosphingolipids. J. Biol. Chem. 275, 15,152ā15,156
Keusch J. J., Manzella S. M., Nyame K. A., Cummings R. D., and Baenziger J. U. (2000) Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of of Ī±1,4 glycosyltransferases conserved in plants, insects and mammals. J. Biol. Chem. 275, 25,315ā25,321
Ghislain J., Lingwood C. A., and Fish E. N. (1994) Evidence for glycosphingolipid modification of the type 1 IFN receptor. J. Immunol. 153, 3655ā3663
Maloney M. D. and Lingwood C. A. (1994) CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J. Exp. Med. 180, 191ā201
Lingwood C. A. and Yiu S. C. K. (1992) Glycolipid modification of Ī±-interferon binding: sequence similarity between Ī±-interferon receptor and the Verotoxin (Shiga-like toxin) B-subunit. Biochem. J. 283, 25,26
Lingwood C. A. (1996) Role of Verotoxin receptors in pathogenesis. Trends Microbiol. 4, 147ā153
Khine A. A. and Lingwood C. A. (2000) Functional significance of globotriaosylceramide in Ī±2 interferon/ type I interferon receptor mediated anti viral activity. J. Cell. Physiol. 182, 97ā108
Maloney M. D., Binnington-Boyd B., and Lingwood C. A. (2000) Globotriaosyl ceramide modulates interferon-Ī±-induced growth inhibition and CD19 expression in Burkittās lymphoma cells. Glycoconj. J. 16, 821ā828
Khine A. A., Firtel M., and Lingwood C. A. (1998) CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J. Cell. Physiol. 176, 281ā292
Williams B. R. G. and Haque S. J. (1997) Interacting pathways of interferon signaling. Semin. Oncol. 24, S9-70āS9-77
Katagiri Y., Mori T., Nakajima H., Katagiri C., Taguchi T., Takeda T., et al. (1999) Activation of Src family kinase induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J. Biol. Chem. 274, 35,278ā35,282
Inward C. D., Williams J., Chant I., Crocker J., Milford D. V., Rose P. E., et al. (1995) Verocytotoxin-1 induces apoptosis in vero cells. J. Infect. 30, 213ā218
Arab S., Murakami M., Dirks P., Boyd B., Hubbard S., Lingwood C., et al. (1998) Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. J. Neurol. Oncol. 40, 137ā150
Taguchi T., Uchida H., Kiyokawa N., Mori T., Sato N., Horie H., et al. (1998) Verotoxins induce apoptosis in human renal tubular epithelium derived. Kidney Int. 53, 1681ā1688
Kiyokawa N., Taguchi T., Mori T., Uchida H., Sato N., Takeda T., et al. (1998) Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J. Infect. Dis. 178, 178ā184
Williams J., Boyd B., Nutikka A., Lingwood C., Barnett-Foster D., Milford D., et al. (1999) A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. Toxicol. Lett. 105, 47ā57
Arab S., Rutka J., and Lingwood C. (1999) Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res. 11, 33ā39
Foster D. B., Abul-Milh M., Huesca M., and Lingwood C. A. (2000) Enterohemorrhagic Escherichia coli induces apoptosis which augments bacterial binding and phosphatidylethanolamine exposure on the plasma membrane outer leaflet. Infect. Immun. 68, 3108ā3115
Mangeney M., Lingwood C. A., Caillou B., Taga S., Tursz T., and Wiels J. (1993) Apoptosis induced in Burkittās lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 53, 5314ā5319
Jones N. L., Islur A., Haq R., Mascarenhas M., Karmali M. A., Perdue M. H., et al. (2000) Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G811āG819
Philpott D. J., Ackerley C. A., Kiliaan A. J., Karmali M. A., Perdue M. H., and Sherman P. M. (1997) Translocation of Verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am. J. Physiol. 273, G1349āG1358
Farkas-Himsley H., Rosen B., Hill R., Arab S., and Lingwood C. A. (1995) Bacterial colicin active against tumor cells in vitro and in vivo is Verotoxin 1. Proc. Natl. Acad. Sci. USA 92 6996ā7000
Arab S., Russel E., Chapman W., Rosen B., and Lingwood C. (1997) Expression of the Verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol. Res. 9, 553ā563
Lala P., Ito S., and Lingwood C. A. (2000) Retroviral transfection of MDCK cells with human MDR1 results in a major increase in globotriaosyl ceramide and 105-106-fold increased cell sensitivity to verocytotoxin. J. Biol. Chem. 275, 6246ā6251
Lannert H., Gorgas K., Meissner I., Wieland F. T., and Jeckel D. (1998) Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. J. Biol. Chem. 273, 2939ā2946
van Helvoort A., Smith A., Sprong H., Fritzsche I., Schinkel A., Borst P., et al. (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidyl choline. Cell 87, 507ā517
Molinari A., Cianfriglia M., Meschini S., Calcabrini A., and Arancia G. (1994) P-Glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int. J. Cancer 59, 789ā795
Salhia B., Rutka J. T., Lingwood C., Nutikka A., and van Furth W. The treatment of malignant meningioma with verotoxin. Neoplasia 4, 304ā311
Lingwood C. A. (1999) Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci. Rep. 19, 345ā354
LaCasse E. C., Saleh M. T., Patterson B., Minden M. D., and Gariā¬y J. (1996) Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 88, 1561ā1567
LaCasse E. C., Bray M. R., Patterson B., Lim W.-M., Perampalam S., Radvanyi L. G., et al. (1999) Shiga-like toxin I receptor on human breast cancer, lymphoma, and myeloma and absence from CD34+ hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 94, 1ā12
Arbus G. S., Grisaru S., and Lingwood C. A. (2000) Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leuk. Res. 24, 857ā864
Newburg D., Chaturvedi P., Lopez E., Devoto S., Feyad A., and Cleary T. (1993) Susceptibilty to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J. Infect. Dis. 168, 476ā479
Kiarash A., Boyd B., and Lingwood C. A. (1994) Glycosphingolipid receptor function is modified by fatty acid content: Verotoxin 1 and Verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269, 11,138ā11,146
Ernest S., Rajaraman S., Megyesi J., and Bello-Reuss E. N. (1997) Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 77, 284ā289
Grupp C., Schmidt F., Braun F., Lorf T., Ringe B., and Muller G. (1998) Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation is tacrolimus the answer? Nephrol. Dial. Transplant. 13, 1629ā1631
Jette L., Beaulieu E., Leclerc J. M., and Beliveau R. (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270, F756āF765
Cooling L. L. W., Walker K. E., Gille T., and Koerner T. A. W. (1998) Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect. Immun. 66, 4355ā4366
Yoshimura K., Fujii J., Yutsuda T., Kikuchi R. T. S., Shirahata S., and Yoshida S. (1998) No direct effects of Shiga toxin 1 and 2 on the aggregation of human platelets in vitro. Thromb. Haemost. 80, 529ā530
Robinson L. A., Lingwood C., Hurley R. M., and Matsell D. G. (1994) The binding and biological effects of E. coli verotoxin (VT-1) on human paediatric glomerular mesangial cells (MC), in Recent Advances in Verocytotoxin-Producing Eschcerichia coli Infections (Karmali M. A. and Goglio A. G., eds.), Elsevier Science Amsterdam, pp. 361ā364
Simon M., Cleary T., Hernandez J., and Abboud H. (1998) Shiga toxin 1 elicits diverse biological responses in mesangial cells. Kidney Intl. 54, 1117ā1127
van Setten P. A., van Hinsbergh V. W., Van der Heuvel L. P., van der Velden T. J., van de Kar N. C., Krebbers R. J., et al. (1997) Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms. J. Am. Soc. Nephrol. 8, 1877ā1888
Holgersson J., Strƶberg N., and Breimer M. E. (1988) Glycolipids of human large intestine: difference in glycolipid expression related to anatomical localization, epithelial/non-epithelial tissue and the ABO, Le and Se phenotypes of the donors. Biochimie 70, 1565ā1574
Holgersson J., Jovall P.-A., and Breimer M. E. (1991) Glycosphingolipids from human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. Biochem. J. 110, 120ā131
Richardson S. E., Rotman T. A., Jay V., Smith C. R., Becker L. E., Petric M., et al. (1992) Experimental verocytotoxemia in rabbits. Infect. Immun. 60, 4154ā4167
Louise C. B., Kaye S. A., Boyd B., Lingwood C. A., and Obrig T. G. (1995) Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin. Infect. Immun. 63, 2765ā2769
Sandvig K., Garred Ć., van Helvoort A., van Meer G., and van Deurs B. (1996) Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol. Biol. Cell. 7, 1391ā1404
Acheson D. W. K., Moore R., De Breucker S., Lincicome L., Jacewicz M., Skutelsky E., et al. (1996) Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect. Immun. 64, 3294ā3300
Hurley B. P., Jacewicz M., Thorpe C. M., Lincicome L. L., King A. J., Keusch G. T., et al. (1999) Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect. Immun. 67, 6670ā6677
Philpott D., McKay D., Mak W., Perdue M., and Sherman P. (1998) Signal transduction pathways involved in enterohemorrhagic Escherichia coli-induced alterations in T84 epithelial permeability. Infect. Immun. 66, 1680ā1687
Foster D. B., Philpott D., Abul-Milh M., Huesca M., Sherman P. M., and Lingwood C. A. (1999) Phosphatidylethanolamine recognition promotes enteropathogenic E. coli and enterohemorrhagic E. coli host cell attachment. Microb. Pathol. 27, 289ā301
Armstrong G. D., McLaine P. N., and Rowe P. C. (1998) Clinical trials of synsorb-Pk in preventing hemolytic uremic syndrome, in Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains (Kaper J. B. and OāBrien A. D., eds.), American Society for Microbiology, Washington, DC, pp. 374ā384
Waddell T. E. and Gyles C. L. (1995) Sodium deoxylcholate facilitates systemic absorption of Verotoxin 2e from pig intestine. Infect. Immun. 63, 4953ā4956
Kim J. H., Lingwood C. A., Williams D. B., Furuya W., Manolson M. F., and Grinstein S. (1996) Dynamic measurement of the pH of the Golgi complex in living cells using retrograde transport of the Verotoxin receptor. J. Cell Biol. 134, 1387ā1399
Johannes L., Tenza D., Anthoy C., and Goud B. (1997) Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J. Biol. Chem. 272, 19,554ā19,561
Kim J. H., Johannes L., Goud B., Antony C., Lingwood C. A., Daneman R., et al. (1998) Non-invasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. Proc. Natl. Acad. Sci. USA 95, 2997ā3002
Saleh M. T. and GariĆ©py J. (1993) Local conformational change in the B-subunit of Shiga-like toxin 1 at endosomal pH. Biochemistry 32, 918ā922
Saleh M., Ferguson J., Boggs J., and Gariepy J. (1996) Insertion and orientation of a synthetic peptide representing the C-terminus of the A1 domain of Shiga toxin into phospholipid membranes. Biochemistry 35, 9325ā9334
MacPherson G., Kushnir N., and Wykes M. (1999) Dendritic cells, B cells and the regulation of antibody synthesis. Immunol. Rev. 172, 325ā334
Lee R. S., Tartour E., van der Bruggen P., Vantomme V., Joyeux I., Goud B., et al. (1998) Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 28, 2726ā2737
Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., et al. (2000) The B-subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165, 3301ā3308
Lechardeur D., Sohn K.-J., Haardt M., Joshi P. B., Monck M., Graham R. W., et al. (1999) Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 6, 482ā497
Facchini L. and Lingwood C. A. (2001) Verotoxin 1 B subunit/lambda Cro chimeric protein specifically targets DNA to globotriaosyl ceramide. Exp. Cell Res. 269, 117ā129
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Lingwood, C.A. (2003). Shiga Toxin Receptor Glycolipid Binding. In: Philpott, D., Ebel, F. (eds) E. coli. Methods in Molecular Medicineā¢, vol 73. Humana Press. https://doi.org/10.1385/1-59259-316-X:165
Download citation
DOI: https://doi.org/10.1385/1-59259-316-X:165
Publisher Name: Humana Press
Print ISBN: 978-0-89603-939-1
Online ISBN: 978-1-59259-316-3
eBook Packages: Springer Protocols